Social media

While multi-pronged global health efforts are essential to combatting HIV, systemic impediments persist. In ICON’s article, learn how drug developers can play a role in reshaping the future of HIV control, and what they ...

What should you consider when choosing a training dataset for your AI-enabled SaMD? Our whitepaper has the answers. Learn about AI models and data best practices and plan for your FDA Pre-Sub. Download it today. https://...

Learn the pros and cons of different AI models for SaMDs. The right model and data training sets are essential to develop your AI-enabled device. Our latest whitepaper lays out the best practices for data and AI models...

Today marked the conclusion of #SCDM Japan in Tokyo, an event dedicated to advancing excellence in clinical data management. Over the past days, industry leaders and professionals came together to explore key topics such...

From exhaustive site visits to intelligent oversight, CRA responsibilities are evolving. ICON’s latest insights in Pharma Times reveal why digital literacy, data interpretation and strategic thinking are now essential sk...

CRAs are at the centre of clinical trial evolution. Risk-based monitoring, intelligent oversight tools and AI are changing how trials are managed. ICON explores what this means for the future in Pharma Times: https://ow....

In the age of technology, site-based assessments are no longer the only ways of collecting valuable data to demonstrate treatment efficacy. The advent and growing acceptance of DHTs, which collect data from patients du...

Site activation delays cost trials time and trust. ICON’s new whitepaper shows how human-centred strategies accelerate startup and improve site satisfaction. Download now: https://ow.ly/qU2y50XB71b

Delays erode site confidence. Learn how ICON helps sponsors maintain momentum and prevent site burnout. Explore the insights: https://ow.ly/3w8u50XB70W

What separates winners from laggards in drug development is recognising the macro trends in the regulatory environment at the highest level of the company and formulating strategies to deliver; - Agility in regulatory st...

What separates winners from laggards in drug development is recognising the macro trends in the regulatory environment at the highest level of the company and formulating strategies to deliver; - Agility in regulatory st...

Recognising ICON’s Environmental, Social & Governance (ESG) commitment through our ICON Cares programme, we are honoured to be named one of the world’s best by TIME/ Statista. This list ranks the world’s 500 most sustain...